Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash Read more about Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
Amgen And Servier Complete Product Collaboration Transaction Read more about Amgen And Servier Complete Product Collaboration Transaction
Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96 Read more about Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
Amgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89 Read more about Amgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
Amgen Announces 2013 Third Quarter Dividend Read more about Amgen Announces 2013 Third Quarter Dividend
Amgen Announces Webcast of 2013 Second Quarter Financial Results Read more about Amgen Announces Webcast of 2013 Second Quarter Financial Results
Amgen And Servier Announce Product Collaboration Read more about Amgen And Servier Announce Product Collaboration
The Lancet Oncology Publishes Results Of XGEVA® (denosumab) In Patients With Giant Cell Tumor Of Bone Read more about The Lancet Oncology Publishes Results Of XGEVA® (denosumab) In Patients With Giant Cell Tumor Of Bone
Amgen Award For Science Teaching Excellence Honors Outstanding Teachers Read more about Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
FDA Approves Amgen's XGEVA® (denosumab) For The Treatment Of Giant Cell Tumor Of Bone Read more about FDA Approves Amgen's XGEVA® (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
